These procedures work through hormonal and anatomical changes that go far beyond simple calorie restriction, producing durable metabolic improvements.
DJB excludes the duodenum and proximal jejunum from food passage, dramatically altering gut hormone secretion. This produces rapid improvement in insulin sensitivity and glucose control, often within days of surgery — before significant weight loss occurs. Particularly effective for lean or mildly overweight patients with T2DM.
SADI-S combines a sleeve gastrectomy with a single anastomosis duodeno-ileal bypass, creating both restriction and significant malabsorption. It achieves some of the highest weight-loss outcomes (80–90% EWL) while treating Type 2 diabetes with up to 90% remission rates. Suitable for super-obese patients with metabolic comorbidities.
The mini gastric bypass (MGB) performed with metabolic intent for patients with Type 2 diabetes and moderate BMI (27.5–35). The procedure reshapes gut anatomy to maximise GLP-1 secretion and improve insulin sensitivity. It achieves 80% T2DM remission with 60–70% excess weight loss and is performed robotically for precision and safety.
For patients with the full metabolic syndrome — diabetes, hypertension, dyslipidaemia, and central obesity — surgical intervention produces dramatic and durable improvements across all parameters. Procedure selection is tailored to BMI, dominant comorbidity, and patient preference, and may include sleeve gastrectomy, bypass, or metabolic-specific procedures.
Metabolic surgery eligibility is broader than traditional bariatric criteria. Dr. Wadhawan follows IDF and DSI guidelines for Asian patients.
Note: These are general guidelines. Every case is assessed individually by Dr. Wadhawan. Patients not meeting standard criteria may still be considered based on severity of disease and response to medical management.
Schedule a consultation with Dr. Randeep Wadhawan at Max Hospital, Dwarka, New Delhi.